Table 1.
Baseline characteristics of the patients stratified by COVID-19 vaccination in Seoul, South Korea.
| Total (n = 2,027,353) | Vaccination | p | ||
|---|---|---|---|---|
| No (n = 308,354) | Yes (n = 1,718,999) | |||
| Gender (n) | 0.028 | |||
| Male | 955,180 (47.11%) | 144,719 (46.93%) | 810,461 (47.15%) | |
| Female | 1,072,173 (52.89%) | 163,635 (53.07%) | 908,538 (52.85%) | |
| Age (years) | 53.07 ± 16.70a | 44.18 ± 16.28a | 54.67 ± 16.26a |
<0.001* <0.001 |
| 20–29 years (n) | 248,526 (12.26%) | 59,155 (19.18%) | 189,371 (11.02%) | |
| 30–39 years (n) | 228,104 (11.25%) | 82,599 (26.79%) | 145,505 (8.46%) | |
| 40–49 years (n) | 271,478 (13.39%) | 67,299 (21.83%) | 204,179 (11.88%) | |
| 50–59 years (n) | 495,117 (24.42%) | 43,916 (14.24%) | 451,201 (26.25%) | |
| 60–69 years (n) | 463,848 (22.88%) | 30,091 (9.76%) | 433,757 (25.23%) | |
| 70–79 years (n) | 226,411 (11.17%) | 13,440 (4.36%) | 212,971 (12.39%) | |
| ≥80 years (n) | 93,869 (4.63%) | 11,854 (3.84%) | 82,015 (4.77%) | |
| Insurance level (n) | <0.001 | |||
| Low | 508,737 (25.09%) | 88,192 (28.60%) | 420,545 (24.46%) | |
| Moderate | 571,150 (28.17%) | 98,141 (31.83%) | 473,009 (27.52%) | |
| High | 947,466 (46.73%) | 122,021 (39.57%) | 825,445 (48.02%) | |
| CCI (n) | <0.001 | |||
| 0 | 1,419,603 (70.02%) | 267,773 (86.84%) | 1,151,830 (67.01%) | |
| 1 | 325,012 (16.03%) | 20,352 (6.60%) | 304,660 (17.72%) | |
| ≥2 | 282,738 (13.95%) | 20,229 (6.56%) | 262,509 (15.27%) | |
| Comorbidity (n) | ||||
| DM | 291,780 (14.39%) | 15,993 (5.19%) | 275,787 (16.04%) | <0.001 |
| Hyperlipidemia | 594,939 (29.35%) | 30,622 (9.93%) | 564,317 (32.83%) | <0.001 |
| HTN | 520,673 (25.68%) | 26,531 (8.60%) | 494,142 (28.75%) | <0.001 |
| COPD | 68,185 (3.36%) | 4,956 (1.61%) | 63,229 (3.68%) | <0.001 |
| Prior COVID-19 infection (n) | 15,090 (0.74%) | 3,099 (1.01%) | 11,991 (0.70%) | < 0.001 |
| 1st vaccination product (n) | ||||
| AZD1222 | 712,187 (41.43%) | 712,187 (41.43%) | ||
| BNT162b2 | 980,129 (57.02%) | 980,129 (57.02%) | ||
| mRNA-1273 | 26,676 (1.55%) | 26,676 (1.55%) | ||
| JNJ-78436735 | 7 (0.00%) | 7 (0.00%) | ||
| 2nd vaccination product (n) | ||||
| AZD1222 | 593,773 (34.54%) | 593,773 (34.54%) | ||
| BNT162b2 | 1,098,521 (63.90%) | 1,098,521 (63.90%) | ||
| mRNA-1273 | 26,698 (1.55%) | 26,698 (1.55%) | ||
| JNJ-78436735 | 7 (0.00%) | 7 (0.00%) | ||
| 1st–2nd vaccination product (n) | ||||
| AZD1222–AZD1222 | 593,766 (34.54%) | 593,766 (34.54%) | ||
| AZD1222–BNT162b2 | 118,413 (6.89%) | 118,413 (6.89%) | ||
| AZD1222–mRNA-1273 | 2 (0.00%) | 2 (0.00%) | ||
| AZD1222–JNJ-78436735 | 6 (0.00%) | 6 (0.00%) | ||
| BNT162b2–AZD1222 | 4 (0.00%) | 4 (0.00%) | ||
| BNT162b2–BNT162b2 | 980,100 (57.02%) | 980,100 (57.02%) | ||
| BNT162b2–mRNA-1273 | 24 (0.00%) | 24 (0.00%) | ||
| BNT162b2–JNJ-78436735 | 1 (0.00%) | 1 (0.00%) | ||
| mRNA-1273–BNT162b2 | 4 (0.00%) | 4 (0.00%) | ||
| mRNA-1273–mRNA-1273 | 26,672 (1.55%) | 26,672 (1.55%) | ||
| JNJ-78436735–AZD1222 | 3 (0.00%) | 3 (0.00%) | ||
| JNJ-78436735–BNT162b2 | 4 (0.00%) | 4 (0.00%) | ||
| 1st–2nd vaccination type (n) | ||||
| No vaccination | 308,354 (15.21%) | 308,354 (100.00%) | ||
| Only mRNA vaccine | 1,006,805 (49.66%) | 1,006,805 (58.57%) | ||
| Only cDNA vaccine | 593,766 (29.29%) | 593,766 (34.54%) | ||
| Heterologous vaccination | 118,428 (5.84%) | 118,428 (6.89%) | ||
| Vaccination interval (days) | 50.71 ± 23.16 | 50.71 ± 23.16 | ||
n number, CCI Charson’s comorbidity index, DM Diabetic mellitus, HTN Hypertension, COPD Chronic obstructive pulmonary diseases, AZD-1222 AstraZeneca ChAdOx1-S recombinant vaccine, BNT162b2 Pfizer-BioNTech Comirnaty, mRNA-1273 Moderna Spikevax, JNJ-78436735 Janssen/Johnson and Johnson COVID-19 Vaccine.
aAll values expressed as mean ± standard deviation.